Arvind Utchanah - Knight Therapeutics Chief Officer
| KHTRF Stock | USD 4.00 0.01 0.25% |
Insider
Arvind Utchanah is Chief Officer of Knight Therapeutics
| Phone | 514 484 4483 |
| Web | https://www.gud-knight.com |
Knight Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0133) % which means that it has lost $0.0133 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0266) %, meaning that it generated substantial loss on money invested by shareholders. Knight Therapeutics' management efficiency ratios could be used to measure how well Knight Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Peter MBA | Bio Path Holdings | 76 | |
| Alan MacKenzie | Bio Path Holdings | N/A | |
| Andrew MBA | Monopar Therapeutics | 53 | |
| Pascalyne Wilson | Cellectis SA | N/A | |
| Michael Schickler | Purple Biotech | 67 | |
| Jeffery MD | Bio Path Holdings | N/A | |
| , MBA | Soleno Therapeutics | N/A | |
| Kyung NamWortman | Cellectis SA | 53 | |
| Valerie Cros | Cellectis SA | N/A | |
| MBA MD | Monopar Therapeutics | 38 | |
| Fabien Sebille | Purple Biotech | 50 | |
| Craig Esq | Cingulate | 51 | |
| MA CPA | Purple Biotech | 59 | |
| Jean Epinat | Cellectis SA | N/A | |
| Anish MD | Soleno Therapeutics | 55 | |
| Joseph Hazelton | Dyadic International | 49 | |
| MSc MSc | Cellectis SA | 54 | |
| Thomas Walker | Bio Path Holdings | N/A | |
| Victoria Rac | Bio Path Holdings | N/A | |
| James MacKaness | Soleno Therapeutics | 61 | |
| Nir Livneh | Purple Biotech | 45 | |
Management Performance
| Return On Equity | -0.0266 | |||
| Return On Asset | -0.0133 |
Knight Therapeutics Leadership Team
Elected by the shareholders, the Knight Therapeutics' board of directors comprises two types of representatives: Knight Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Knight. The board's role is to monitor Knight Therapeutics' management team and ensure that shareholders' interests are well served. Knight Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Knight Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, Ex Chairman | ||
| Arvind Utchanah, Chief Officer | ||
| Leopoldo Bosano, VicePres Operations | ||
| Susan Emblem, Global HR | ||
| Jody Engel, Sr Devel | ||
| Jeff Martens, Global Commercial | ||
| Daniela Marino, Global Compliance |
Knight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Knight Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0266 | |||
| Return On Asset | -0.0133 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.08) % | |||
| Current Valuation | 354.32 M | |||
| Shares Outstanding | 113.96 M | |||
| Shares Owned By Insiders | 30.54 % | |||
| Shares Owned By Institutions | 12.90 % | |||
| Price To Earning | 15.30 X | |||
| Price To Book | 0.69 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Knight Pink Sheet
Knight Therapeutics financial ratios help investors to determine whether Knight Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.